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Dr W. Moore (Los Angeles, Calif): How do we know that, in
fact, that there has been myocardial damage just because you
happen to have an asymptomatic troponin release in the absence of
EKG changes?
Our cardiologists often describe the so called troponin leak
phenomenon, particularly when there may be an episode of hyper-
tension in the perioperative interval. I think your increased inci-
dence of mortality may simply represent a higher risk group in
which the troponin leak population occurred. You showed that
there was a higher incidence of prior myocardial infarction and
other comorbidities in the troponin leak group. Therefore I won-
der if the troponin event is simply a marker for the higher risk
group rather than a morbid event in of itself?
Dr Schouten: As shown on the slides on pathophysiology of
troponin release, there must be a compromised membrane of the
cardiomyocytes for troponin to be released into the bloodstream.
This implies that there must be cardiac damage one way or the
other.
We also did a subgroup analysis for patients who stayed at the
ICU for at least two days after surgery, more or less the critically ill
patients with episodes of hypotension, and also, in that group of
patients, those with troponin release did much worse than patients
without troponin release. While the exact pathophysiology is not
entirely clear for this group of patients, the main message is that if
you have a patient with cardiac troponin release, either it’s symp-
tomatic or asymptomatic, they do much worse on the long term.
These patients probably will benefit from more aggressive medical
therapy and more aggressive follow-up on the long term.
Dr J. Ricotta (Washington, DC): I was actually going to ask
you to elaborate on that last question. In your units, do you have a
protocol for how you evaluate these patients after you find that
they have asymptomatic troponin release. Do you have a standard
algorithm for evaluation and management?
Dr Schouten: Currently we are performing another study in
this patient population with asymptomatic cardiac troponin T
release. It’s called the DECREASE VII trial. And what we do in
that trial is that we randomize patients who have asymptomatic
cardiac troponin release to receive either clopidogrel on top of beta
blockers, statins and aspirin, or placebo on top of this medication.
In terms of cardiac stress testing or coronary angiography, it
depends on whether or not the patient will get eventually EKGEKG abnormalities, we will not perform any other additional
cardiac evaluation or cardiac tests.
Dr P.Goodney (Lebanon, NH): We studied similar questions
in our vascular study group in Northern New England. One of the
questions we struggled with was a lack of a multivariate finding for
beta blockers and statins. I noticed your model similarly didn’t
include those medical regimens. I thought you might comment on
that.
Dr Schouten: At our unit all patients are on beta blockers, so
it is impossible to find any benefit or harm of beta blockers in this
study. What we have found in this study in terms of medication
use—I did not include it in this presentation because of time
restraints is that patients who were not on statins, which were
approximately 30% of the patients, had a worse outcome than
patients on statins. The odds ratio was approximately 0.65. So
statins seem to work. But on the other hand, nowadays, all our
patients will get statins anyway.
Dr P. Gloviczki (Rochester, Minn): Have you looked at
preoperative cardiac variables, cardiac risk factors, and would they
predict your elevated troponin release?
Dr Schouten: One of the slides showed a multivariate analysis
for predictors of asymptomatic cardiac troponin release, and these
risk factors were more or less the same as for more hard endpoints
like myocardial infarction and cardiac deaths.
Dr F. Mussa (New York, NY): Along the same line of Dr.
Gloviczki’s question, did you go back and change your preopera-
tive workup for those patients based on your troponin release?
Nowadays, we’re doing less extensive workup for patients with
stable coronary disease undergoing vascular or endovascular pro-
cedures.
Dr Schouten: No, we did not change our preoperative
workup based on these study results. Our current preoperative
policy is based on earlier DECREASE studies, and in particular
DECREASE II: patients with 1 risk factor can undergo surgery
quite safely with beta blockers and statins. Also patients with 2 risk
factors will benefit from statins and beta blockers and can undergo
vascular surgery quite safely.
The problem is with patients who have 3 or more risk factors.
In those patients we perform cardiac stress testing, in all patients.
But that’s not something that we’ve investigated in this study and
it’s not something which we will change based on these study
results.
